Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de 48 meses para avaliar a eficácia a longo prazo de Elocta na saúde das articulações (A-MORE)

18 de setembro de 2026 atualizado por: Swedish Orphan Biovitrum

Um estudo observacional multicêntrico de 48 meses para avaliar a eficácia a longo prazo do Elocta na saúde das articulações

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

Tipo de estudo

Observacional

Inscrição (Real)

427

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Berlin, Alemanha
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn, Alemanha
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt, Alemanha
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt, Alemanha
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg, Alemanha
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover, Alemanha
        • Medizinische Hochschule Hannover
      • Hanover, Alemanha
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg, Alemanha
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf, Alemanha
        • HZRM Hämöphilie Zentrum Rhein Main
      • München, Alemanha
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
      • Riyadh, Arábia Saudita
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh, Arábia Saudita
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh, Arábia Saudita
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh, Arábia Saudita
        • Riyadh Military Hospital (P.S.M.C)
      • Ljubljana, Eslovênia
        • University Medical Centre Ljubljana Division of Paediatrics
      • Barcelona, Espanha
        • Sant Johan De Deu
      • Barcelona, Espanha
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, Espanha
        • Hospital Vall d'Hebron
      • Cruces, Espanha
        • Hospital Universitario Cruces
      • Donostia / San Sebastian, Espanha
        • Hospital Universitario Donostia
      • Murcia, Espanha
        • Hospital Virgen de la Arrixaca
      • Málaga, Espanha
        • Hospital Universitario Carlos Haya
      • Navarro, Espanha
        • Complejo Hospitalario de Navarra
      • Oviedo, Espanha
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca, Espanha
        • Hospital Universitario Son Espases
      • Seville, Espanha
        • Hospital Universitario Virgen del Rocío
      • Vigo, Espanha
        • Hospital Alvaro Cunqueiro
      • Tallinn, Estônia
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn, Estônia
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Helsinki, Finlândia
        • Helsinki University Central Hospital, New Children Hospital
      • Turku, Finlândia
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
      • Thessaloniki, Grécia
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki, Grécia
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Groningen, Holanda
        • University Medical Center Groningen/UMCG
      • Bari, Itália
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena, Itália
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova, Itália
        • Giannina Gaslini Institute
      • Milan, Itália
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma, Itália
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome, Itália
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino, Itália
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Muscat, Omã
        • The Royal Hospital
      • Canterbury, Reino Unido
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London, Reino Unido
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
      • Gothenburg, Suécia
        • Hematologimottagning Sahlgrenska
      • Malmö, Suécia
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Bern, Suíça
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne, Suíça
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen, Suíça
        • Zentrum für Labormedizin
      • Zurich, Suíça
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
      • Brno, Tcheca
        • University Hospital Brno
      • Ostrava, Tcheca
        • University Hospital Ostrava
      • Prague, Tcheca
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

Descrição

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

Outros nomes:
  • efmoroctocog alfa
  • ELOCTATE
  • rFVIIIFc

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Joint health: Target joint development
Prazo: 48 months

Number of target joints

48 months
Joint health: Target joint resolution
Prazo: 48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
Prazo: 48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Prazo: 48 months

Number of joint bleeding events per year, for treated bleeds

48 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Prazo: 48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Prazo: 48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
Prazo: 48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Prazo: 48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Prazo: 48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Prazo: 48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
Prazo: 48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
Prazo: 48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
Prazo: 48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
Prazo: 48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
Prazo: 48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
Prazo: 48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Prazo: 48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Prazo: 48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
Prazo: 48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
Prazo: 48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
Prazo: 48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
Prazo: 48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Prazo: 48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
Prazo: 48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Prazo: 48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Prazo: 48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Prazo: 48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Prazo: 48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Prazo: 48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Prazo: 48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Prazo: 48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Prazo: 48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Prazo: 48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Prazo: 48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Prazo: 48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Study Physician, Swedish Orphan Biovitrum

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de março de 2020

Conclusão Primária (Real)

4 de maio de 2026

Conclusão do estudo (Real)

4 de maio de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

20 de fevereiro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de março de 2020

Primeira postagem (Real)

3 de março de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • Sobi.Elocta-005

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .